PuSH - Publikationsserver des Helmholtz Zentrums München

Ketelhuth, D.F.J.* ; Lutgens, E.* ; Bäck, M.* ; Binder, C.J.* ; Van den Bossche, J.* ; Daniel, C.* ; Dumitriu, I.E.* ; Hoefer, I.* ; Libby, P.* ; O'Neill, L.* ; Weber, C.* ; Evans, P.*

Immunometabolism and atherosclerosis: perspectives and clinical significance- A position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.

Cardiovasc. Res. 115, 1385-1392 (2019)
Verlagsversion Postprint DOI PMC
Open Access Green
Inflammation is an important driver of atherosclerosis, and the favourable outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial revealed the large potential of anti-inflammatory drugs for treatment of cardiovascular disease, especially in patients with a pro-inflammatory constitution. However, the complex immune reactions driving inflammation in the vascular wall in response to an atherosclerotic microenvironment are still being unravelled. Novel insights into the cellular processes driving immunity and inflammation revealed that alterations in intracellular metabolic pathways are strong drivers of survival, growth and function of immune cells. This position paper therefore presents a brief overview of the recent developments in the immunometabolism field, focusing on its role in atherosclerosis. We will also highlight the potential impact of immunometabolic markers and targets in clinical cardiovascular medicine.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
ISSN (print) / ISBN 0008-6363
e-ISSN 1755-3245
Zeitschrift Cardiovascular Research
Quellenangaben Band: 115, Heft: 9, Seiten: 1385-1392 Artikelnummer: , Supplement: ,
Verlag Oxford University Press
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed